GSK has upgraded its sales and profits forecasts following a surge from HIV and oncology medications as chief executive Dame Emma Walmsley prepares to depart the pharmaceutical giant.

Company shares climbed on Wednesday as a consequence, reaching their highest point in more than a year.

The London -headquartered drugs manufacturer said recent performance has positioned it to achieve revenue growth of between 6% and 7% for 2025. Previously, it had guided towards the upper end of a 3% to 5% range.

GSK also informed investors that core operating profits will span 9% to 11%, having earlier indicated this would likely sit at the top of a 6% to 8% bracket.

These revisions emerged as it disclosed that revenue increased by 7% to £8.55 billion, compared with the preceding year.

The advancem

See Full Page